Deal Watch: Roche Links With SemaThera, Acquires GenMark Diagnostics
Executive Summary
Tempest goes public via a reverse merger with Millendo. Takeda inks its ninth deal of 2021, a discovery pact with BridGene around its chemoproteomics technology.
You may also be interested in...
Bausch Investors Initially Pessimistic Following B+L Spinout
With its IPO of Bausch + Lomb bringing in $630m in proceeds, Bausch Health is moving forward with its plan to use the eye care unit’s separation to pay down its remaining debt.
Bausch Hopes B+L Spin-Out Will 'Unlock' The Value Of Eye-Care Business
Bausch Health is paying down its debt with a $630m IPO for its Bausch + Lomb eyecare product business.
Big Pharma’s Busiest Deal-Makers In 2021 Were Less Prolific Than In 2020
Totals for aggregate deals and in the M&A, alliance and divestment categories were similar among the 10 busiest deal makers from 2020 to 2021, but COVID-19 may have driven a more hectic deal-making pace overall in 2020.